NasdaqGS:MRNABiotechs
Why Moderna (MRNA) Is Down 6.6% After Its ‘Moderna 2.0’ Cancer-Vaccine Pivot - And What's Next
In late March 2026, Moderna participated in the World Vaccine Congress Washington and the 4th annual Entrepreneurship Summit, where senior leaders highlighted its evolving mRNA vaccine and cancer-therapy ambitions while the company continued to address operational and legal challenges.
Together with a multi‑billion‑dollar patent settlement and progress toward individualized cancer vaccines, these events underline Moderna’s attempt to reset its long‑term direction beyond COVID‑19.
Next,...